Looks like Fda may have even already approved a Phase 3 study for AXA1125 , so for Bucillamine there would be a good possibility it would be approved for a phase 3 Long covid Trial right away?, getting ready for work now and still sleepy lol.... After a at least 2B buyout hopefully : ) Found some more info here.
AXA1125 showed statistically significant improvement in fatigue. They were able to correlate the improvement in physical function with improvement in mitochondrial function biomarkers. Phase 3 study has been approved by the FDA for #LongCovid as they try to get approval. pic.twitter.com/kTCtetaFS5
Ps, and it looks like Bucillamine would work much better than this...AXA1125 is just an amino acid?
Many people might scoff at the fact that this is just an amino acid complex including myself. But after the presentation I get the idea that this is a therapeutic dose of specific amino acids and has been used in other diseases. Seems to improve mitochondrial and endothelial func
pps. and just noticed this...probably cheaper (and equally effective) to take just NAC instead of AXA1125 . My bet.
not surprised. There is reasonable evidence for NAC to be effective in #MECFS. Probably cheaper (and equally effective) to take just NAC instead of AXA1125 . My bet.